Form 4: Theodore R. Samuels II Reports Acquisition of Centene Corp Stock

Director Theodore R. Samuels II reports acquiring 377 shares of Centene Corp common stock and holding 18,000 shares indirectly through a family trust.

Summary

• Theodore R. Samuels II, a director of Centene Corp, reported a transaction on June 30, 2024.
• He acquired 377 shares of common stock at $0, bringing his direct holdings to 13,287.979 shares, which includes 2,916 shares of restricted stock units subject to vesting requirements.
• He also indirectly owns 18,000 shares through a revocable family trust where he serves as co-trustee.
• Samuels also holds options to buy 10,000 shares of common stock at an exercise price of $80.57, exercisable from February 7, 2025, and expiring on February 7, 2032.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a routine disclosure of stock transactions by a company director. The acquisition of shares is a mildly positive signal, but not significantly impactful on its own.

Positives

• The director's acquisition of shares could be interpreted as a positive signal about his confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis.
• Comparing Samuels' transactions to those of other Centene executives or executives at similar healthcare companies (e.g., UnitedHealth Group, Anthem) could provide further context.
• Analyzing the ratio of insider buys to sells across the industry can offer insights into overall market sentiment.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates